Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study

David Price, Maarten j. h. i. Beekman* (Corresponding Author), Walter javier Mattarucco, Rocio martina Barriga-Acevedo, Hao-Chien Wang, Dina v. Diaz, Adel Khattab, Manuel Pacheco gallego, Ashraf Al zaabi, Hisham Farouk, Darush Attar-Zadeh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)

Abstract

This post-hoc analysis of the SABINA III study evaluated the association of short-acting β2-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48.9 years). Of the 2810 patients prescribed ≥3 SABA canisters, 776 (27.6%) also purchased ≥1 SABA OTC. This subset of 776 patients reported the highest disease burden; 73.2% had ≥1 severe exacerbation and 55.7% had uncontrolled asthma. Asthma-related outcomes worsened with any SABA OTC purchase, regardless of SABA prescriptions; disease burden was the highest in patients with ≥3 SABA prescriptions and ≥1 SABA OTC purchase vs 1–2 SABA prescriptions only (86% lower odds of having at least partly controlled asthma and 124% increased incidence of severe asthma (both P < 0.001). These findings emphasize the need to implement policy changes to restrict SABA purchase without prescriptions and ensure access to affordable asthma care.
Original languageEnglish
Article number34
Number of pages10
Journalnpj Primary Care Respiratory Medicine
Volume34
Issue number1
Early online date1 Nov 2024
DOIs
Publication statusPublished - 1 Nov 2024

Bibliographical note

Acknowledgements
AstraZeneca funded all the SABINA studies and was involved in designing the study, developing the study protocol, conducting the study, and performing the analyses. AstraZeneca was given the opportunity to review the manuscript before submission and funded medical writing support. Writing and editorial support was provided by Praveen Kaul, PhD, of Cactus Life Sciences (part of Cactus Communications), Mumbai, India, in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460) and fully funded by AstraZeneca.

Keywords

  • asthma
  • health policy

Fingerprint

Dive into the research topics of 'Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study'. Together they form a unique fingerprint.

Cite this